Research Funded by Box Rallies

Melanoma Margins Trial: A Phase III, Multi-centre Randomised Controlled Trial

Monitoring a patient’s real-time response to a new immunotherapy

Novel Treatment Targets in Low-Grade Serous Ovarian Cancer

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Predicting clinical response to breast cancer therapy – the immune signature approach

Preventing people with immune deficiencies from developing cancer

Preventing the outgrowth of cancers that spread to bone

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

Rational Targeting of the Hedgehog Pathway to Treat Osteosarcoma

Real-time dose monitoring for patient safety in radiation therapy.

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Reversing treatment resistance in ER+ breast cancer

Reversing treatment resistance in melanoma

Selective manipulation of tumour-stroma signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer

Switching off the spread of triple-negative breast cancer

Targeting Innate Chemoresistance in Lung Adenocarcinoma

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy